PGE2 promotes renal carcinoma cell invasion through activated RalA
- PMID: 22580611
- PMCID: PMC3421051
- DOI: 10.1038/onc.2012.161
PGE2 promotes renal carcinoma cell invasion through activated RalA
Abstract
Incidence of kidney cancer is on the rise, and a better understanding of molecular mechanisms involved in the cancer invasion and metastasis is required for the development of curative therapeutics. In this study, we report that the proinflammatory cytokine prostaglandin E2 (PGE2) induces the malignant SN12C, but not benign HK2 kidney cell invasion. The PGE2 increases SN12C cell invasion through a signal pathway that encompasses EP2 and EP4, Akt, small GTPase RalA and Ral·GTP inactivator RGC2. The results support the idea that targeted interference of EP2/EP4 signal to RalA·GTP may provide benefit to patients diagnosed with advanced kidney cancer.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
References
-
- Siegel RWE, Brawley O, Jemal A. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36. - PubMed
-
- Young AN, Dale J, Yin-Goen QQ, Harris WB, Petros JA, Datta MW, et al. Current trends in molecular classification of adult renal tumors. Urology. 2006;67:873–80. - PubMed
-
- Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010;7:327–38. - PubMed
-
- Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer - when TKIs are not enough. Nat Rev Clin Oncol. 2009;6:478–87. - PubMed
-
- Schlesinger-Raab A, Treiber U, Zaak D, Holzel D, Engel J. Metastatic renal cell carcinoma: Results of a population-based study with 25 years follow-up. Eur J Cancer. 2008;44:2485–95. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
